Written and maintained by CASRAI Editorial Board
Last updated
BioMedTracker (BMT) is an independent database, operated by Pharma Intelligence UK Limited as part of Evaluate (a Norstella company), that tracks developmental drugs through the FDA approval process. It combines pipeline tracking, regulatory and clinical catalysts, deals and a Likelihood of Approval (LOA) estimate that pairs historical approval rates with analyst opinion.
Pipeline intelligence of this kind sits next to regulatory affairs in the pharmaceutical industry and the sponsor relationships described in the pharmaceutical CRO industry sector overview.
What it is
BioMedTracker is a subscription research database for developmental drugs. Its operator describes it as an independent database that follows drugs through the FDA approval process, and Evaluate’s product page presents it as a web platform with a searchable interface, automated alerts and human insight.
Its signature output is the Likelihood of Approval (LOA). According to the operator’s research standards, LOA estimates combine two elements: an objective figure based on historical approval rates for drugs in the same regulatory phase, and a subjective opinion from the Senior Analysts based on publicly released clinical trial data. The product page describes the LOA as proprietary and used alongside expert analyst commentary.
Teams that plan studies can use the database as one reference point for what competing programs look like, alongside their own clinical trial protocol design work.
Who runs it and what it covers
The research standards page names Pharma Intelligence UK Limited, part of Evaluate (a Norstella company), as the operator. Evaluate’s product page lists BioMedTracker among its products and says it is used by professionals across pharma, biotech, CROs, professional services, finance and consulting.
Evaluate’s page reports coverage of over 35,000 drugs and over 1,800 listed targets. The search menus show the other record types: companies, diseases, trials, events, deals, catalysts and reports.
The operator states several policies on independence:
- The Senior Analysts alone produce the drug and company opinions, and no outside party, including biotech or pharma companies, investment banks or investment firms, influences their content, conclusions or timing.
- The company is not a broker/dealer or investment banking firm and has no relationship with any such firm.
- It does not issue buy or sell recommendations on any stock; it publishes opinions on the likelihood that developmental drugs will be approved.
- Its information comes only from public sources such as company press releases, medical conference presentations, SEC filings, company websites and slide presentations.
Access is by subscription. Evaluate’s site separately describes data delivery through Snowflake, structured feeds and selected APIs; check with the vendor which of these apply to a given BioMedTracker license.
How to search or use it
The sign-in link (“Login”) is in the top navigation bar of the BioMedTracker site. The site’s own menus offer these search tools:
- Search All drop-down: Search for Products, Companies, Diseases, Trials, Targets, Events, Deals, Catalysts and Reports.
- Advanced Search menu: Advanced Catalyst Search, Advanced Company Search, Advanced Drug Search, Advanced Event Search, Advanced Deal Search, FDA AdComm Searches, Key Opinion Leader Search, Trial Comparison Search and Saved Searches.
Typical uses follow from these names. Advanced Drug Search and Advanced Company Search locate programs and sponsors; Advanced Catalyst Search and FDA AdComm Searches surface upcoming catalysts; Trial Comparison Search lines up study designs for comparison, which pairs naturally with the clinical data management tools a team already uses; Advanced Deal Search covers deals; and Saved Searches keep a query for reuse. Evaluate’s product page also mentions automated alerts.
Strengths and limits
Strengths:
- Stated analyst independence: the operator publishes its policy on broker/dealer separation and outside influence.
- Two-part LOA: a historical phase baseline is combined with analyst opinion, and the method is described in the operator’s standards.
- Catalyst and event search: dedicated modules for catalysts, events and FDA advisory committee meetings.
Limits:
- Public sources only: because information comes only from public sources, non-public developments are not represented.
- Analyst opinion: the subjective part of the LOA is an opinion, not a measurement.
- Subscription access: some content is marked “Subscribers Only” on the site.
Alternatives
| Resource | Provider | Type of resource |
|---|---|---|
| BioMedTracker | Pharma Intelligence UK Limited / Evaluate (Norstella) | Subscription drug pipeline, catalyst and LOA database |
| Evaluate Pharma | Evaluate (Norstella) | Another product in Evaluate’s product list |
| ClinicalTrials.gov | U.S. National Library of Medicine | Public registry of clinical studies |
Status such as orphan drug designation is another reference point to consider next to pipeline data.
FAQ
What does Likelihood of Approval (LOA) measure in BioMedTracker?
It is an estimate of the likelihood that a developmental drug will be approved. Per the operator’s research standards, it combines an objective figure based on historical approval rates for drugs in the same regulatory phase with a subjective opinion from the Senior Analysts based on publicly released clinical trial data.
Where does BioMedTracker get its information?
The operator states that information comes only from public sources, such as company press releases, medical conference presentations, SEC filings, company websites and slide presentations.
Does BioMedTracker give stock recommendations?
No. The operator says it does not issue buy or sell recommendations on any stock and is not a broker/dealer or investment banking firm. It does publish opinions on whether developmental drugs will be approved.
Who publishes BioMedTracker?
Pharma Intelligence UK Limited, part of Evaluate, which is a Norstella company.
How does BioMedTracker differ from ClinicalTrials.gov?
ClinicalTrials.gov is a public registry of clinical studies. BioMedTracker is a subscription database that adds catalyst, deal and company records and an LOA estimate on top of public-source information.
Sources
Checked 2026-11-07.
- BioMedTracker research standards and policies, Pharma Intelligence UK Limited: https://www.biomedtracker.com/Standards.cfm
- Biomedtracker solution overview, Evaluate: https://www.evaluate.com/solutions/biomedtracker/
- BioMedTracker site (search menus and sign-in): https://www.biomedtracker.com/
- ClinicalTrials.gov: https://clinicaltrials.gov/
